Page last updated: 2024-12-06

glutarimide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Glutarimide is a cyclic imide derived from glutaric acid. It is a colorless solid with a melting point of 102-103 °C. Glutarimide has been studied for its potential applications in various fields, including:
* **Synthesis:** Glutarimide is a versatile building block for the synthesis of other organic compounds, including pharmaceuticals, agrochemicals, and polymers.
* **Effects:** Glutarimide exhibits anticonvulsant activity and has been investigated as a potential treatment for epilepsy. It has also been shown to possess anti-inflammatory and analgesic properties.
* **Importance:** The study of glutarimide is important for understanding its potential therapeutic benefits and exploring its applications in drug discovery and development.
* **Why it is studied:** Glutarimide's unique chemical structure and pharmacological properties make it an attractive target for drug development. Researchers are interested in exploring its potential as a therapeutic agent for various conditions, including epilepsy, inflammation, and pain.
* **Other research:** Recent research has also explored the use of glutarimide derivatives in the development of novel materials, such as polymers and catalysts.'

Cross-References

ID SourceID
PubMed CID70726
CHEMBL ID3763941
CHEBI ID5435
SCHEMBL ID26618
MeSH IDM0051303

Synonyms (42)

Synonym
CHEBI:5435
nsc-58190
nsc58190
einecs 214-340-4
nsc 58190
brn 0110052
inchi=1/c5h7no2/c7-4-2-1-3-5(8)6-4/h1-3h2,(h,6,7,8
2,6-piperidinedione
2,6-diketopiperidine
glutarimide ,
piperidine-2,6-dione ,
C07275
1121-89-7
nsc-168666
glutarimide, 98%
chembl3763941 ,
bdbm50146597
G0269
A802510
AKOS009159209
mv728o9612 ,
5-21-09-00557 (beilstein handbook reference)
unii-mv728o9612
FT-0626735
SCHEMBL26618
2,6-dioxopiperidine
piperidin-2,6-dione
DTXSID7074452
mfcd00006670
J-002721
acetylglycinamide impurity b
CS-W023103
nsc 168666
Q3109315
SY049583
DS-15888
EN300-41708
9uz ,
AMY400
F11946
SB42939
Z424792856

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
piperidones
dicarboximideAn imide in which the two acyl substituents on nitrogen are carboacyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cereblon isoform 4Magnetospirillum gryphiswaldenseIC50 (µMol)162.10003.53006.31007.8000AID1277063; AID1277066
Cereblon isoform 4Magnetospirillum gryphiswaldenseKi101.33330.64203.94289.6000AID1277067; AID1277070; AID1569040
Protein cereblonHomo sapiens (human)IC50 (µMol)135.80000.28601.70663.0000AID1277064
Protein cereblonHomo sapiens (human)Ki103.10001.49006.580010.0000AID1277068
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
protein ubiquitinationProtein cereblonHomo sapiens (human)
positive regulation of Wnt signaling pathwayProtein cereblonHomo sapiens (human)
negative regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
positive regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
negative regulation of monoatomic ion transmembrane transportProtein cereblonHomo sapiens (human)
locomotory exploration behaviorProtein cereblonHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein bindingProtein cereblonHomo sapiens (human)
transmembrane transporter bindingProtein cereblonHomo sapiens (human)
metal ion bindingProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
nucleusProtein cereblonHomo sapiens (human)
cytoplasmProtein cereblonHomo sapiens (human)
cytosolProtein cereblonHomo sapiens (human)
membraneProtein cereblonHomo sapiens (human)
perinuclear region of cytoplasmProtein cereblonHomo sapiens (human)
Cul4A-RING E3 ubiquitin ligase complexProtein cereblonHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1277066Inhibition of MANT-uracil binding to Magnetospirillum gryphiswaldense cereblon isoform 4 Y101F mutant by FRET assay2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID1277063Inhibition of MANT-uracil binding to wild type Magnetospirillum gryphiswaldense cereblon isoform 4 by FRET assay2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID1277064Inhibition of MANT-uracil binding to human CRBN (delta 1 to 315) by FRET assay2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID1569040Inhibition of MANT-uracil binding to wild-type Magnetospirillum gryphiswaldense CRBN isoform 4 by FRET assay2019Journal of medicinal chemistry, 07-25, Volume: 62, Issue:14
De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives.
AID1277070Inhibition of MANT-uracil binding to Magnetospirillum gryphiswaldense cereblon isoform 4 Y101F mutant by Cheng-Prusoff equation analysis2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID1277069Inhibition of MANT-uracil binding to Caenorhabditis elegans CRBN (delta 1 to 15) by Cheng-Prusoff equation analysis2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID1277065Inhibition of MANT-uracil binding to Caenorhabditis elegans CRBN (delta 1 to 15) by FRET assay2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID1277067Inhibition of MANT-uracil binding to wild type Magnetospirillum gryphiswaldense cereblon isoform 4 by Cheng-Prusoff equation analysis2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
AID1277068Inhibition of MANT-uracil binding to human CRBN (delta 1 to 315) by Cheng-Prusoff equation analysis2016Journal of medicinal chemistry, Jan-28, Volume: 59, Issue:2
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (115)

TimeframeStudies, This Drug (%)All Drugs %
pre-199055 (47.83)18.7374
1990's4 (3.48)18.2507
2000's19 (16.52)29.6817
2010's30 (26.09)24.3611
2020's7 (6.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.97 (24.57)
Research Supply Index4.80 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index56.82 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.83%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other120 (99.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Study of Lenalidomide in Combination With Rituximab and Ibrutinib in Relapsed and Refractory CLL and SLL [NCT02200848]Phase 15 participants (Actual)Interventional2014-04-30Terminated(stopped due to Recruitment difficulties and toxicity)
Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Efficacy and Safety of XC8 in Patients With the Eosinophilic Phenotype of Bronchial Asthma [NCT04674137]Phase 270 participants (Actual)Interventional2020-12-16Completed
Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess Efficacy, Safety and Optimal Dose of XC8 in Patients With Partly Controlled Bronchial Asthma Receiving Stable Treatment With Low Doses of Inhaled Corticosteroids With or Wi [NCT03450434]Phase 2120 participants (Actual)Interventional2016-09-20Completed
Double-blind, Randomized, Dose-escalating, Placebo-controlled Study to Assess Pharmacokinetics, Safety, and Tolerability of XC-8 After Single and Multiple Oral Doses in Healthy Volunteers [NCT02882217]Phase 132 participants (Actual)Interventional2016-08-31Completed
A Double-blind, Randomized, Placebo-controlled Study of the Safety and Tolerability of Increasing Doses of XC8 After Single and Repeated Oral Administration in Healthy Volunteers [NCT03441815]Phase 128 participants (Actual)Interventional2015-02-14Completed
Clinical Study to Assess Efficacy, Safety, Tolerability and Optimal Dose Ranging of XC8 in Doses 20, 100 and 200 mg Once Daily in Patients With Uncomplicated Influenza or Other Acute Respiratory Viral Infections (ARVI) [NCT03441373]Phase 2/Phase 3320 participants (Actual)Interventional2016-02-03Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]